Status:
RECRUITING
Determining Prognostic Immune Markers in Patients With Ovarian Cancer
Lead Sponsor:
Leiden University Medical Center
Conditions:
Epithelial Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary p...
Detailed Description
Tumor material, ascites (if possible) and blood samples for immune monitoring will be collected from patients with primary and recurrent EOC undergoing surgery, chemotherapy and/or immunotherapy.
Eligibility Criteria
Inclusion
- Patients with (suspicion of) primary or recurrent EOC with an indication for surgery, chemotherapy and/or immunotherapy.
- Age ≥18 years.
- WHO performance status 0-2.
- Accessible for treatment and follow-up.
- Written informed consent.
Exclusion
- Other active malignancy in past 5 years prior to entry into the study, except for treated non-melanoma skin cancer.
- Any known severe infection like HIV, hepatitis A, B and C.
- Receiving immune suppressive treatment.
- Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.
Key Trial Info
Start Date :
August 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03862677
Start Date
August 15 2020
End Date
January 31 2027
Last Update
April 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Leiden University Medical Center
Leiden, Netherlands